Vaxcyte
PCVX

Vaxcyte (PCVX) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
BTIGMaintainedBuy$89.00 from $85.00Feb 26, 2026
GuggenheimMaintainedBuy$116.00Feb 2, 2026
NeedhamMaintainedBuy$110.00 from $90.00Jan 7, 2026
BTIGMaintainedBuy$85.00Nov 10, 2025
Goldman SachsInitiated CoverageNeutral$38.00Sep 12, 2025
Cantor FitzgeraldInitiated CoverageOverweightApr 22, 2025
NeedhamMaintainedBuy$90.00Apr 8, 2025
NeedhamMaintainedBuy$90.00 from $140.00Apr 1, 2025
B of A SecuritiesMaintainedBuy$137.00 from $157.00Apr 1, 2025
Goldman SachsMaintainedBuy$100.00 from $138.00Apr 1, 2025
GuggenheimMaintainedBuy$160.00Mar 12, 2025
NeedhamMaintainedBuy$140.00Feb 26, 2025
GuggenheimMaintainedBuy$160.00Feb 26, 2025
NeedhamMaintainedBuy$14.00Feb 11, 2025
Goldman SachsInitiated CoverageBuy$135.00Dec 20, 2024
NeedhamMaintainedBuy$140.00Nov 6, 2024
Cantor FitzgeraldMaintainedOverweightNov 6, 2024
MizuhoMaintainedOutperform$163.00 from $113.00Sep 10, 2024
B of A SecuritiesMaintainedBuy$140.00 from $101.00Sep 4, 2024
BTIGMaintainedBuy$160.00 from $98.00Sep 3, 2024

Frequently asked questions

  • What is the latest analyst rating on PCVX?

    On Feb 26, 2026, BTIG maintained Vaxcyte at Buy with a price target of $89.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.